Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 81
Filter
1.
Cornea ; 41(5): 562-571, 2022 May 01.
Article in English | MEDLINE | ID: covidwho-1778962

ABSTRACT

PURPOSE: The purpose of this study was to describe the rationale and design of the Zoster Eye Disease Study (ZEDS). METHODS: ZEDS is a National Eye Institute-supported randomized clinical trial designed to determine whether 1 year of suppressive valacyclovir in patients with herpes zoster ophthalmicus (HZO) reduces complications because there is currently no high-quality evidence to support its use. Eligible patients are 18 years and older, immunocompetent, have a history of a typical rash at disease onset, and have had a record of active epithelial or stromal keratitis or iritis within 1 year before enrollment. Exclusion criteria include estimated glomerular filtration rate less than 45 or pregnancy. The primary endpoint is the time to first occurrence of new or worsening dendriform epithelial keratitis, stromal keratitis without or with ulceration, endothelial keratitis, or iritis due to HZO during 12 months of study treatment requiring prespecified treatment changes. The study has 80% power to detect a 30% difference between treatment groups, with a 30% rate of endpoints by 1 year assumed among controls. Secondary and exploratory questions include whether there is a persistent treatment benefit during the 6 months after treatment, whether development of postherpetic neuralgia varies by treatment group, and whether vaccinations against herpes zoster affect study outcomes and coronavirus disease 19 status. RESULTS: Over approximately 4 years, over 400 study participants have been enrolled. CONCLUSIONS: ZEDS aims to provide scientific evidence on whether suppressive valacyclovir treatment improves outcomes in HZO and should become the standard of care.


Subject(s)
COVID-19 , Herpes Zoster Ophthalmicus , Herpes Zoster , Neuralgia, Postherpetic , Antiviral Agents/therapeutic use , Herpes Zoster Ophthalmicus/complications , Herpes Zoster Ophthalmicus/diagnosis , Herpes Zoster Ophthalmicus/drug therapy , Humans , Neuralgia, Postherpetic/diagnosis , Neuralgia, Postherpetic/drug therapy , Neuralgia, Postherpetic/epidemiology , Valacyclovir/therapeutic use
2.
Indian J Public Health ; 66(1): 83-85, 2022.
Article in English | MEDLINE | ID: covidwho-1776455

ABSTRACT

Ever since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, science has unraveled much knowledge on SARS-CoV-2 which has led to extraordinary and unprecedented progress in developing COVID-19 vaccines. Several adverse cutaneous reactions, ranging from more common local injection site reaction, neutrophilic and pustular drug reactions to flare-up of preexisting dermatoses, have been reported with currently available vaccines. We report a case series of 7 patients who developed herpes zoster (HZ) following the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (recombinant). HZ following vaccination is a rare entity. The occurrence of HZ in the patients presented in this series within the time window 1-21 days after vaccination defined for increased risk and postulated dysregulation of T-cell-mediated immunity, suggests that the ChAdOx1 nCoV-19 coronavirus vaccine (recombinant) could probably be a trigger for reactivation of varicella zoster virus to cause HZ in them.


Subject(s)
COVID-19 , Herpes Zoster , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Herpes Zoster/epidemiology , Herpes Zoster/etiology , Herpes Zoster/prevention & control , Herpesvirus 3, Human , Humans , India , SARS-CoV-2 , Vaccination/adverse effects
3.
J Med Case Rep ; 16(1): 127, 2022 Mar 25.
Article in English | MEDLINE | ID: covidwho-1759774

ABSTRACT

PURPOSE: To describe two cases of herpetic anterior uveitis after inoculation of the first dose of Pfizer-BioNTech coronavirus disease 2019 vaccine. METHODS: Case 1: a healthy 92-year-old Caucasian woman developed symptomatic unilateral anterior uveitis for 3 days after Pfizer-BioNTech coronavirus disease 2019 vaccination (Pfizer Inc.). The episode fully resolved with topical and oral antiviral treatment. Case 2: a previously healthy 85-year-old Caucasian woman with left hemicranial signs of herpes zoster infection, associated with herpetic keratouveitis for 3 days after Pfizer-BioNTech coronavirus disease 2019 vaccination. Treatment with topical antibiotics and both oral and topical antiherpetic medication was administered, and she recovered successfully in 5 weeks. CONCLUSION: Clinicians should be aware of the possibility of eye inflammation in the form of herpetic reactivation after coronavirus disease 2019 vaccination.


Subject(s)
COVID-19 , Herpes Zoster , Uveitis, Anterior , Uveitis , Aged, 80 and over , COVID-19 Vaccines/adverse effects , Female , Herpes Zoster/complications , Humans , Uveitis, Anterior/diagnosis , Uveitis, Anterior/drug therapy , Uveitis, Anterior/etiology
4.
J Korean Med Sci ; 37(8): e61, 2022 Feb 28.
Article in English | MEDLINE | ID: covidwho-1714982

ABSTRACT

There are several previous reports that infection or reactivation of varicella zoster virus (VZV) can occur after coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Herein, we report a rare case of VZV meningitis in breakthrough COVID-19. An 18-years-old male visited the emergency room, presenting with a headache and fever of up to 38.4°C for 5 days. He received the second dose of BNT162b2 mRNA SARS-CoV-2 vaccine 7 weeks prior to symptom onset. The symptoms persisted with headache, fever, and nausea. His cerebrospinal fluid (CSF) showed an elevated opening pressure of 27 cm H2O, 6/µL red blood cells, 234/µL white blood cells (polymorphonuclear leukocytes 3%, lymphocytes 83%, and other 14%), 43.9 mg/dL protein, and 59 mg/dL glucose, and CSF polymerase chain reaction (PCR) test was positive for VZV. Also, he was diagnosed with COVID-19 by reverse transcriptase-PCR examining upper and lower respiratory tract. We administered intravenous acyclovir for 12 days, and he was discharged without any neurologic complication.


Subject(s)
COVID-19/complications , Coinfection/etiology , Herpes Zoster/etiology , Meningitis, Viral/etiology , SARS-CoV-2 , Acyclovir/therapeutic use , Adolescent , COVID-19 Vaccines , Coinfection/drug therapy , Herpes Zoster/drug therapy , Humans , Male , Meningitis, Viral/drug therapy
7.
Cutis ; 109(1): E5-E7, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1707291

ABSTRACT

Herpes zoster (HZ) was suspected as a predictive cutaneous manifestation of COVID-19, with a debated prognostic significance. We report a series of 5 cases of HZ occurring after vaccination with a nucleoside-modified messenger RNA (mRNA) COVID-19 vaccine (Comirnaty, Pfizer-BioNTech). These new cases do not prove causality between COVID-19 vaccination and HZ. The pathophysiologic mechanism remains elusive, but local vaccine-induced immunomodulation may be involved. The occurrence of HZ does not justify avoiding the second injection of vaccine due to the benefit of vaccination.


Subject(s)
COVID-19 , Herpes Zoster Vaccine , Herpes Zoster , COVID-19 Vaccines , Herpes Zoster/diagnosis , Herpes Zoster/prevention & control , Herpes Zoster Vaccine/adverse effects , Humans , Nucleosides/adverse effects , RNA, Messenger , SARS-CoV-2
8.
J Med Case Rep ; 16(1): 45, 2022 Jan 24.
Article in English | MEDLINE | ID: covidwho-1650762

ABSTRACT

BACKGROUND: The spectrum of clinical manifestations and differential diagnosis associated with coronavirus disease 2019 is broad, ranging from fever and cutaneous eruptions to respiratory distress or even neurological disorders. Coexisting multipathogen infections significantly increase the complexity of the proper diagnostic and therapeutic approach and correlate with the rate of intensive care unit admissions and in-hospital mortality. CASE PRESENTATION: We present a case of multipathogen respiratory infection with severe acute respiratory syndrome coronavirus 2, varicella zoster virus, and polymicrobial tracheobronchitis in a 48-year-old Caucasian male hospitalized after traumatic brain injury. The patient tested positive for severe acute respiratory syndrome coronavirus 2 infection upon admission. During his stay in the intensive care unit, the patient developed a vesicular exanthema along with respiratory failure and signs of septic shock. CONCLUSION: This case of an adult presenting with severe acute respiratory syndrome coronavirus 2 infection and simultaneous primary varicella zoster virus infection illustrates the importance of considering coinfections in patients with coronavirus disease 2019 with unusual clinical manifestations.


Subject(s)
COVID-19 , Coinfection , Herpes Zoster , Adult , Herpesvirus 3, Human , Humans , Male , Middle Aged , SARS-CoV-2 , Ventilators, Mechanical
10.
Hum Vaccin Immunother ; 18(1): 2027196, 2022 Dec 31.
Article in English | MEDLINE | ID: covidwho-1631418

ABSTRACT

Due to COVID-19, vaccinations dropped in 2020 and 2021. We estimated the impact of reduced recombinant zoster vaccine (RZV) use on herpes zoster (HZ) cases, complications, and quality-adjusted life-year (QALY) losses among older adults. Various scenarios were compared with Markov models using data from national sources, clinical trials, and literature. Missed series initiations were calculated based on RZV distributed doses. In 2020, 3.9 million RZV series initiations were missed, resulting in 31,945 HZ cases, 2,714 postherpetic neuralgia cases, and 610 lost QALYs. Scenarios further projected disease burden increases if individuals remain unvaccinated in 2021 or the same number of initiations are missed in 2021. Health professionals should emphasize the importance of vaccination against all preventable diseases during the COVID-19 era.


Subject(s)
COVID-19 , Herpes Zoster Vaccine , Herpes Zoster , Neuralgia, Postherpetic , Aged , COVID-19/epidemiology , COVID-19/prevention & control , Cost-Benefit Analysis , Herpes Zoster/epidemiology , Herpes Zoster/prevention & control , Herpesvirus 3, Human , Humans , Neuralgia, Postherpetic/epidemiology , Neuralgia, Postherpetic/prevention & control , Pandemics , United States/epidemiology , Vaccination , Vaccines, Synthetic
11.
Gastroenterol Hepatol ; 44(8): 587-598, 2021 Oct.
Article in English, Spanish | MEDLINE | ID: covidwho-1626213

ABSTRACT

Patients with certain immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), have an increased risk of severe infectious diseases than the general population, which are mainly associated with the immunosuppressive treatments that they receive. These treatments act on the immune system through different mechanisms, causing different degrees of immunosuppression and a variable risk depending on whether the pathogen is a virus, bacteria or fungus. This article reviews the most relevant literature on the subject, which was selected and discussed by a panel of experts. The aim of this article is to review the risk of infections in patients with IBD and RA, and the potential preventive measures.


Subject(s)
Arthritis, Rheumatoid/therapy , Bacterial Infections/prevention & control , Biological Therapy/adverse effects , Immunosuppressive Agents/adverse effects , Inflammatory Bowel Diseases/therapy , Janus Kinase Inhibitors/adverse effects , Virus Diseases/prevention & control , Arthritis, Rheumatoid/immunology , COVID-19/etiology , Hepatitis A/prevention & control , Hepatitis B/prevention & control , Herpes Zoster/prevention & control , Humans , Inflammatory Bowel Diseases/immunology , Influenza, Human/prevention & control , Pneumococcal Infections/prevention & control , Risk Factors , Tuberculosis, Pulmonary/prevention & control , Vaccination Coverage , Vaccines, Inactivated/administration & dosage
12.
Viruses ; 14(2)2022 01 19.
Article in English | MEDLINE | ID: covidwho-1625634

ABSTRACT

The Varicella-zoster virus (VZV) or human herpes virus 3 is a neurotropic human alpha herpes virus responsible for chickenpox/varicella and shingles/Herpes zoster (HZ). This review will focus on HZ. Since HZ is secondary to varicella, its incidence increases with age. In children and youngsters, HZ is rare and associated to metabolic and neoplastic disorders. In adults, advanced age, distress, other infections (such as AIDS or COVID-19), and immunosuppression are the most common risk factors. HZ reactivation has recently been observed after COVID-19 vaccination. The disease shows different clinical stages of variable clinical manifestations. Some of the manifestations bear a higher risk of complications. Among the possible complications, postherpetic neuralgia, a chronic pain disease, is one of the most frequent. HZ vasculitis is associated with morbidity and mortality. Renal and gastrointestinal complications have been reported. The cornerstone of treatment is early intervention with acyclovir or brivudine. Second-line treatments are available. Pain management is essential. For (secondary) prophylaxis, currently two HZV vaccines are available for healthy older adults, a live attenuated VZV vaccine and a recombinant adjuvanted VZV glycoprotein E subunit vaccine. The latter allows vaccination also in severely immunosuppressed patients. This review focuses on manifestations of HZ and its management. Although several articles have been published on HZ, the literature continues to evolve, especially in regard to patients with comorbidities and immunocompromised patients. VZV reactivation has also emerged as an important point of discussion during the COVID-19 pandemic, especially after vaccination. The objective of this review is to discuss current updates related to clinical presentations, complications, and management of HZ.


Subject(s)
Disease Management , Herpes Zoster/drug therapy , Herpes Zoster/prevention & control , Herpesvirus 3, Human/pathogenicity , Herpesvirus Vaccines/immunology , Herpes Zoster/complications , Herpes Zoster/physiopathology , Herpesvirus Vaccines/administration & dosage , Herpesvirus Vaccines/classification , Humans , Immunocompromised Host , Incidence , Latent Infection/virology , Morbidity , Neuralgia, Postherpetic/virology , Risk Factors , Vaccination , Vaccines, Synthetic/administration & dosage
17.
Reumatismo ; 73(3)2021 Nov 22.
Article in English | MEDLINE | ID: covidwho-1534345

ABSTRACT

Since the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic outbreak, vaccines gained a growing role. Possible vaccine-related side effects range from minor local events to more prominent systemic manifestations up to anaphylactic reactions. A heterogeneous spectrum of cutaneous reactions has been reported, ranging from local injection site reactions to urticarial and morbilliform eruptions, pernio/chilblains and zoster flares. Here, we describe a case of varicella zoster virus reactivation following mRNA coronavirus 2019 vaccine and discuss the available literature upon the topic published so far.


Subject(s)
COVID-19 , Herpes Zoster , Spondylitis, Ankylosing , COVID-19 Vaccines , Humans , RNA, Messenger , SARS-CoV-2
18.
Infection ; 50(2): 289-293, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1527525

ABSTRACT

The first cases of COVID-19 were reported in Wuhan, China, in December 2019. Skin manifestations of COVID-19 vary, among which herpes zoster has recently been found to be associated with the infection. We studied the available literature regarding COVID-19-associated herpes zoster (HZ). We searched the PubMed and Scopus databases for available literature till 20th of May 2021 using the following terms: 'Herpes zoster' or 'Varicella zoster virus' and "COVID-19" or "coronavirus disease" or "SARS-CoV-2". This search revealed 87 publications, of which 29 articles met the inclusion criteria. A total of 29 patients had HZ associated with COVID-19 infection. The patients' ages ranged from 7 to 82 years, averaging 56 years. Thirteen patients (45%) were men and 16 (55%) women. We summarized the demographic data, clinical data, comorbidities, treatment used, lymphocyte count, and distribution and timeline of HZ rash in COVID patients. Lymphopenia was prevalent in 86.6% of patients (where lymphocyte data were available). We discuss possible causes of HZ due to COVID-19. More and larger studies are needed to confirm any relationship between these two infections; however, this study may pave the way for similar studies on this topic.


Subject(s)
COVID-19 , Herpes Zoster , Adolescent , Adult , Aged , Aged, 80 and over , COVID-19/complications , Child , China , Female , Herpes Zoster/complications , Herpes Zoster/epidemiology , Herpesvirus 3, Human , Humans , Male , Middle Aged , SARS-CoV-2 , Young Adult
19.
Am J Case Rep ; 22: e934658, 2021 Nov 17.
Article in English | MEDLINE | ID: covidwho-1524601

ABSTRACT

BACKGROUND Ramsay Hunt syndrome is a rare form of herpes zoster caused by the reactivation of the varicella-zoster virus in the geniculate ganglion. The main clinical manifestations are peripheral facial palsy, vesicular rash in the ear, and ipsilateral auricular pain, and sometimes vertigo. COVID-19 is a new multisystemic infectious disease that, in addition to common respiratory manifestations, it is known to affect the immune system, primarily depressing cellular immunity. CASE REPORT A 54-year-old woman was admitted to our hospital with an acute vestibular syndrome and diplopia. She had been diagnosed 3 years prior with interstitial lung disease for which she was taking methylprednisolone. At admission, she tested positive for SARS-CoV-2. In the following days, she developed a sixth nerve palsy on the left side and a right peripheral facial palsy on the right side, followed by a typical zoster rash on the ipsilateral ear. One month later, she developed acute severe hearing loss on the right side. There were no COVID-19 symptoms during her stay in our hospital. The MRI showed Gd enhancement of both facial nerves. Under antiviral and corticoid treatment, the evolution was favorable, with marked improvement at 6 months. CONCLUSIONS COVID-19 increases the risk for herpes zoster infection, probably through induced depression of the cellular immunity. Our case suggests Ramsay Hunt syndrome can be the presenting symptom and sometimes the only symptom of COVID-19. This also seems to be true for other cranial neuropathies, and we recommend testing these patients even if there are no other manifestations.


Subject(s)
COVID-19 , Herpes Zoster Oticus , Herpes Zoster , Polyneuropathies , Female , Herpes Zoster/complications , Herpes Zoster/diagnosis , Herpes Zoster Oticus/diagnosis , Herpes Zoster Oticus/drug therapy , Humans , Middle Aged , SARS-CoV-2
20.
Int J Dermatol ; 61(3): 379-380, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1522708
SELECTION OF CITATIONS
SEARCH DETAIL